A Prospective, Randomized Controlled Study to Evaluate the Efficacy and Safety of Durvalumab Combined With Neoadjuvant Therapy in Patients With Local Advanced Esophageal Squamous Cell Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- pathological response
研究概览
简要总结
This is a study to evaluate the efficacy and safety of preoperative treatment with durvalumab combined with neoajuvant therapy (carboplatin, paclitaxel with/without radiation) in locally advanced resectable oesophageal squamous carcinoma.
详细描述
The primary objective of the study is to assess the tumor response (by irRECIST) and pathological response of preoperative treatment with durvalumab combined with neoadjuvant therapy (carboplatin, paclitaxel with/without radiation).
Secondary objectives are:
To assess completion of treatment with durvalumab combined with chemotherapy with/without radiation treatment.
To assess toxicities of durvalumab in combination with chemoradiation. [Time Frame: up to 1 year] To assess completion of chemotherapy with/without radiation treatment. To assess withdrawal rate from surgery. To assess delay rate from surgery. To assess R0 resection rate. To assess post-operative complications. Progression Free Survival. [ Time Frame: up to 24 months ] Overall Survival. [ Time Frame: up to 24 months ]
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven squamous cell carcinoma of the esophagus.
- •Surgical resectable (T3 or T4b, N0 or N+, M0), as determined by Endoscopic Ultra Sound (EUS),PET/CT, Esophageal MRI and enhanced CT scan of neck, thorax and abdomen.
- •Tumor length longitudinal ≤ 10 cm; if larger than 10 cm, inclusion should be discussed with the principal investigator.
- •Tumor does not involve gastro-esophageal junction.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate hematological, renal and hepatic functions defined as:
- •neutrophiles ≥ 1.5 x 109/L platelets ≥ 100 x 109/L alanine transaminase≤2 x upper normal limit hemoglobin ≥ 5.6 mmol total bilirubin ≤ 1.5 x upper normal limit creatinine clearance (Cockroft) ≥60 ml/min
- •Written, voluntary informed consent.
排除标准
- •Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer.
- •T1, T2 tumors or in situ carcinoma.
- •metastatic oesophageal cancer.
- •Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
- •Previous chemotherapy, radiotherapy, and/or treatment with checkpoint inhibitors.
- •Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery.
- •Pulmonary fibrosis and/or severely impaired lung function precluding major surgery.
- •Pre-existing motor or sensory neurotoxicity greater than WHO grade
- •Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •Dementia or altered mental status that would prohibit the understanding and giving of informed consent
- •Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine.
- •Has an active infection requiring systemic therapy which has not resolved 3 days (simple infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior to the first dose of trial treatment.
- •Has a diagnosis of acute or chronic hepatitis B, hepatitis C, known immunodeficiency or human immunodeficiency virus (HIV).
- •Patients with prior allogeneic stem cell or solid organ transplantation.
研究组 & 干预措施
durvalumab and neoadjuvant therapy
durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Durvalumab (Drug)
durvalumab and neoadjuvant therapy
durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Carboplatin (Drug)
durvalumab and neoadjuvant therapy
durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Paclitaxel (Drug)
durvalumab and neoadjuvant therapy
durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Radiotherapy 23 x 1.8 Gy (Radiation)
normal saline and neoadjuvant therapy
normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Carboplatin (Drug)
normal saline and neoadjuvant therapy
normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Paclitaxel (Drug)
normal saline and neoadjuvant therapy
normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
干预措施: Radiotherapy 23 x 1.8 Gy (Radiation)
结局指标
主要结局
pathological response
时间窗: up to 12 months
assess the pathological response (by CAP classification) of preoperative treatment with durvalumab combined with neoadjuvant therapy
tumor response
时间窗: up to 12 months
assess the tumor response (by irRECIST) of preoperative treatment with durvalumab combined with neoadjuvant therapy
次要结局
- Percentage delay of surgery due to durvalumab related complications(up to 3 months)
- R0 resection rate(up to 3 months)
- Incidence and severity of post-operative complications to the Dindo classification(up to 3 months)
- Percentage withdrawal rate from surgery due to durvalumab related complications(up to 3 months)
- Percentage completion of treatment with durvalumab combined with chemotherapy with/without radiation treatment(up to 3 months)
- Percentage completion of chemotherapy with/without radiation treatment(up to 3 months)
- Progression free survival(up to 24 months)
- Overall survival(up to 24 months)
- Incidence and severity of toxicity(up to 12 months)